74 results
Page 2 of 4
8-K
EX-99.1
vkoisovgor p9
15 Mar 22
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
7:04am
8-K
EX-99.1
lyxev58y7 d3jzb
10 Nov 21
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
4:05pm
8-K
EX-99.1
fmyyxerodi30 ps
5 Aug 21
Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates
5:31pm
8-K
EX-99.1
a1jmh arhz
13 May 21
Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
7:34am
8-K
EX-99.1
aq1l34vh01c5t mlhj
29 Mar 21
Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
5:26pm
8-K
EX-99.1
8h842442 3giqu78c6
16 Nov 20
Windtree Therapeutics Reports Third Quarter 2020
7:40am
8-K
EX-99.1
i62p0h8p36rye1vpg4qt
1 Oct 20
Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients
7:36am
8-K
EX-99.1
qkbqktwmmwvtwn0a05
29 Sep 20
Other Events
7:37am
8-K
EX-99.1
zm62tbj781dpxzg
14 Aug 20
Windtree Therapeutics Reports Second Quarter 2020 Financial Results and Provides Key Business Updates
6:07am
8-K
EX-99.1
v0ya6l17h0g2mdh
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
8-K
EX-99.2
ytju2 ds12cj
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
424B4
91ye1v j4sio3t0xgori
21 May 20
Prospectus supplement with pricing info
6:04am
8-K
EX-99.1
caa2 pk2gvmt
14 May 20
Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates
8:12am
S-1/A
0dp1ginv66xmg
6 May 20
IPO registration (amended)
5:31pm